Showing results (31-40 of 61) with videos related to

Sort By:
Pageof 7
Blood Neoplasia|August 12, 2025
GCK inhibition enhances iberdomide antimyeloma effects by promoting IKZF1 degradation via a CRBN-independent mechanismShirong Li, Josefine Krüger, Guifen Liu, et al.
American Journal of Hematology|May 31, 2016
Incidence, etiology, and outcome of pleural effusions in allogeneic hematopoietic stem cell transplantationDipenkumar Modi, Hyejeong Jang, Seongho Kim, et al.
Blood|September 14, 2021
Phase 1a/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosisCamille Vanessa Edwards, Nisha Rao, Divaya Bhutani, et al.
Blood|July 25, 2025
Safety and Efficacy of Elranatamab in Patients with Relapsed and/or Refractory immunoglobulin Light-Chain AmyloidosisPedro Vianna, Rajshekhar Chakraborty, Shahrier Hossain, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 18, 2013
Evaluating the effects of lenalidomide induction therapy on peripheral stem cells collection in patients undergoing autologous stem cell transplant for multiple myelomaDivaya Bhutani, Jeffrey Zonder, Jason Valent, et al.
American Journal of Hematology|June 20, 2026
Long-Term Outcomes of Mayo Stage IIIb AL Amyloidosis Treated With Daratumumab-Based Frontline TherapySimon Zhen, Sorina Nicoleta Bandelita, Divaya Bhutani, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 20, 2019
Use of Bisphosphonates in Elderly Patients With Newly Diagnosed Multiple MyelomaSiyang Leng, Yizhen Chen, Wei-Yann Tsai, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|July 3, 2024
Outcomes of venetoclax-based therapy in patients with t(11;14) light chain amyloidosis after failure of daratumumab-based therapyDanai Dima, Michael Hughes, Mark Orland, et al.
Pageof 7